Ready-to-Use Neural Organoids for Real-Time Functional Insight

CNS-3D Organoids provide a high-throughput in vitro human model for neurotoxicity, seizure liability, synaptogenesis, neurogenesis, excitotoxicity, ion channel activity, and neuropharmacology applications.

CNS Complex in vitro Model

CNS-3D Organoids

Organoids grow to diameters between 500-800µm, differentiate into both neurons and astrocytes
Spontaneous and coordinated network activity can be captured in real-time with high-throughput functional assessment (FLIPR).
Rigorous quality control process ensures lot to lot consistency prior to shipment.
Schematic of the CNS-3D organoid generation procedure. Induced pluripotent stem cells (iPSCs) are expanded before being derived into neural progenitor cells (NPCs) which is then cryopreserved to serve as the starting material for each CNS-3D organoid production batch. Over the course of 6-weeks, organoids grow to diameters between 500-800µm, differentiate into both neurons and astrocytes, and exhibit spontaneous coordinated network activity. Shown above are waveforms measured on FLIPR (Molecular Devices).

Cell Types

CNS-3D organoids are comprised of ~50% neurons and ~50% astrocytes which result from the co-differentiation of a single neural progenitor cell suspension. Of this neuron population, 95% are glutamatergic (excitatory) neurons and ~5% are GABAergic (inhibitory) neurons.

SnRNAseq analysis confirms that CNS-3D Organoids exhibit a mature biological profile, characterized by a large supporting astrocyte population and a small progenitor cell population. Additionally, their transcriptomic profiles show strong correlations with both fetal and human cortical biology, further validating their physiological relevance.
CNS-3D Organoids are delivered in ready-to-use 96- and 384-well plates containing functional organoids derived from human iPSCs. These cortical organoids are comprised of a mix of neurons (MAP2) and astrocytes (GFAP) confirmed qualitatively through ICC and quantitatively by single nuclei RNAseq.

Reproducibility & Stability

Organoid consistency provides reliable results the first time, without the need for repeated experiments
Longitudinal and chronic (weeks-long) treatment paradigms are enabled by consistent, stable pharmacological responses
Validated 4-week use window supports flexible assay workflows while maintaining data quality
(A) CNS-3D organoids are batch-produced in monthly builds and exhibit exceptional uniformity in diameter—both within individual plates and across plates in a single batch—overcoming the morphological variability that typically plagues organoid biology.
(B) The remarkable batch-to-batch reproducibility in organoid diameter has been demonstrated across both 384-well and 96-well lots historically, with CVs across batches guaranteed under 5%

3D Model Comparison

Product Formats

CNS-3D Organoids are designed for high-throughput screening and available in assay ready 96- and 384-well plate formats. A proprietary media hibernation system allows for shipping to any lab around the world.
96-well assay ready microplates
384-well assay ready microplates

Quality Control of Organoid Production

In addition to functional characterization, brightfield imaging is performed to confirm consistent organoid size (500-800µm diameter, CV within plate <5%; 98% organoids present), expected ratios of neurons and astrocytes via immunocytochemistry (ICC), and sterility (mycoplasma, anaerobic, aerobic, fungal).
A certificate of analysis will be included in every shipment, providing the aforementioned data as well as EC/IC50 and robust z-prime values for FLIPR screening.
Insert caption here

CNS-3D Organoid Resources